Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Clinical Trial: "Evaluation of the Combination of Nimotuzumab and Cisplatin-Vinorelbine in First Line Chemotherapy in the Survival of Patients With Recurring-Persistent Cervical Carcinoma"

NCT02083211 is registered in ClinicalTrials.gov with National Institute of Cancerología as lead sponsor.

NCT NCT02083211
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02083211 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Clinical Trial: "Evaluation of the Combination of Nimotuzumab and Cisplatin-Vinorelbine in First Line Chemotherapy in the Survival of Patients With Recurring-Persistent Cervical Carcinoma"
Lead sponsor
National Institute of Cancerología
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2010
Completion date
June 30, 2014
Enrollment
168 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer recurrent or persistent, monoclonal antibody in cervical cancer treatment, palliative treatment